The prices for active pharmaceuticals ingredients (API) will recover in FY27 due to the implementation of minimum import price (MIP) starting from 29 January 2026 and China’s withdrawal value-added ...
The National Drug Policy, 1982 marked a revolutionary shift in Bangladesh's pharmaceutical industry. Following its adoption, domestic production surged, local companies gained market dominance, and ...
Pakistan's pharmaceutical industry, valued at Rs. 748 billion, faces challenges with API imports. Localizing API production could enhance economic stability and healthcare affordability.
On Sept. 5, the FDA announced an import alert and green list for glucagon-like peptide-1 (GLP-1) active pharmaceutical ingredient (API) manufacturers. The FDA included manufacturers on the green list ...
In a significant regulatory development aimed at controlling substandard imports, the Government of India has imposed price-based import restriction on sulfadiazine API, a key active pharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results